Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1 STATE OF OKLAHOMA
1
2 2nd Session of the 60th Legislature (2026)
2
3 SENATE BILL 1658 By: Jett
3
4
4
5
5
6 AS INTRODUCED
6
7 An Act relating to health care; creating the Informed
7 Consent and Medical Transparency Act; providing short
8 title; declaring legislative intent; imposing certain
8 duties on drug manufacturers, hospitals, and health
9 care providers; authorizing certain civil actions;
9 providing certain construction; providing for
10 noncodification; providing for codification; and
10 providing an effective date.
11
11
12
12
13 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
13
14 SECTION 1. NEW LAW A new section of law not to be
14
15 codified in the Oklahoma Statutes reads as follows:
15
16 A. This act shall be known and may be cited as the "Informed
16
17 Consent and Medical Transparency Act".
17
18 B. The Legislature declares that informed consent is a
18
19 cornerstone of ethical medical practice and falls within the
19
20 traditional authority of the State of Oklahoma to protect the
20
21 health, safety, and welfare of its citizens. Nothing in this act
21
22 shall be construed to alter or conflict with federal drug approval
22
23 or labeling requirements; rather, it establishes independent state
23
24
24
Req. No. 2346 Page 1
1 duties of disclosure and transparency to ensure Oklahomans can make
1
2 informed medical decisions.
2
3 SECTION 2. NEW LAW A new section of law to be codified
3
4 in the Oklahoma Statutes as Section 355.5 of Title 59, unless there
4
5 is created a duplication in numbering, reads as follows:
5
6 A. 1. Each manufacturer of a drug, vaccine, or biologic
6
7 distributed in this state shall prepare a plain-language summary of
7
8 known or reasonably suspected side effects or adverse events that
8
9 are material to informed consent, including those that are rare but
9
10 serious or life-threatening.
10
11 2. The summary shall be written in a manner understandable to
11
12 health care providers and patients and shall be updated whenever the
12
13 manufacturer, in the exercise of reasonable care, becomes aware of
13
14 new or credible safety information that would materially affect
14
15 informed consent.
15
16 3. Manufacturers shall provide the current summary to the State
16
17 Board of Pharmacy for publication on a public website and to
17
18 hospitals, pharmacies, and licensed prescribers within this state.
18
19 4. Nothing in this subsection shall require alteration of
19
20 federally approved labeling or submission of data to any federal
20
21 agency.
21
22 B. 1. Hospitals, health care facilities, and licensed health
22
23 care providers shall ensure that each patient, or the patient's
23
24
24
Req. No. 2346 Page 2
1 legal guardian, receives the manufacturer's current summary prior to
1
2 administration or prescription of any drug, vaccine, or biologic.
2
3 2. Suspected adverse events or side effects shall be documented
3
4 through existing electronic medical record systems and transmitted
4
5 to the State Board of Pharmacy within ten (10) business days.
5
6 3. Any hospital or health care provider that discourages,
6
7 obstructs, or retaliates against an employee for good-faith
7
8 documentation or reporting of such an event shall be jointly and
8
9 severally liable for injuries proximately caused by the suppression
9
10 or failure to report.
10
11 C. 1. A manufacturer, hospital, or provider that negligently
11
12 fails to comply with this section shall be liable for damages
12
13 proximately caused by the resulting lack of informed consent.
13
14 2. Any patient injured as a result of noncompliance may bring a
14
15 civil action for damages, including reasonable attorney fees.
15
16 3. Discovery in such actions shall be liberally construed in
16
17 favor of transparency, including access to relevant safety data,
17
18 communications, and adverse-event documentation.
18
19 4. The Attorney General or any district attorney may also bring
19
20 an action under the Oklahoma Consumer Protection Act for patterns of
20
21 noncompliance.
21
22 D. This section shall be liberally construed to promote
22
23 transparency and informed decision-making. It shall not be
23
24
24
Req. No. 2346 Page 3
1 interpreted to mandate or prohibit any treatment or to impose
1
2 requirements preempted by federal law.
2
3 SECTION 3. This act shall become effective November 1, 2026.
3
4
4
5 60-2-2346 DC 1/13/2026 9:16:46 PM
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 2346 Page 4Every fact on this page links to its source, starting with the official bill record.